FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average I	ourden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					or Sec	tion 3	su(n) o	tne I	nvestmer	nt Co	mpany Act c	1940								
Name and Address of Reporting Person* McNeill Jonathan					2. Issuer Name and Ticker or Trading Symbol Dyne Therapeutics, Inc. [DYN]									tionship of Report all applicable) Director			10% O	wner		
(Last)		3. Date of Earliest Transaction (Month/Day/Year) 06/12/2023								X	Officer (give title below) See F		Other (s below) Lemarks		specify					
1560 TRAPELO ROAD					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)									
(Street) WALTHAM MA 02451														X	X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication														
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Table	I - No	n-Deriva	tive S	ecui	ities	Acc	uired,	Dis	posed of	, or E	Benefi	cially	/ Owr	ned				
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day)				Execu y/Year) if any		Deemed ution Date, / th/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (. Disposed Of (D) (Instr. 3 5)			3, 4 and Sec Bei Ow Fol		Amount of curities eneficially whed ollowing		: Direct r ect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) (D)	or Pri	се	Report Transa (Instr.	ted action(s) 3 and 4)					
Common	023			S ⁽¹⁾		1,000	D	\$	13 ⁽²⁾	64,391 ⁽³⁾			D							
Common Stock 06/13/20						.023			S	1,259(4)		D	\$1	2.43	63,132 ⁽³⁾		D			
		Tab	le II -	Derivativ (e.g., pu											Owne	ed				
1. Title of Derivative Security (Instr. 3)	ative Conversion or Exercise (Month/Day/Year) Execution Date, if any			4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)					7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and		Der Sec (Ins	Price of erivative ecurity 1str. 5)	9. Number o derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y G	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amoun or Numbe of Shares	r						

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of \$12.95 to \$13.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
- 3. Includes 59,326 unvested RSUs.
- 4. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

Remarks:

Senior Vice President of Business Development

/s/ Richard Scalzo, Attorneyin-Fact 06/14/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.